drugset
drugset / Trial / NCT00228540

Study to Assess Satisfaction With Modafinil Treatment in Children and Adolescents With ADHD

NCT00228540 ↗

Phase 3 Completed Cephalon
Non-randomizedFactorialOpen-labelTreatment

Summary

An 8-week, Open-Label Study to Characterize the Response to Modafinil (85mg Film-Coated Tablet) Treatment at Dosages up to 425mg/Day in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD) (With an Open-Ended Extension Period)

Timeline

Start
2005-09
Primary completion
—
Completion
2006-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Modafinil Small molecule 85 mg —
Subject Modafinil Small molecule 425 mg —

Indications

attention deficit-hyperactivity disorder